Patents by Inventor Sirpa Jalkanen
Sirpa Jalkanen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230046617Abstract: A vascular adhesion protein-1 (VAP-1) inhibitor can be used as a regulator of reactive oxygen species (ROS) concentration in ex vivo culturing of hematopoietic stem cells, which enables a method of producing an expanded population of hematopoietic5 stem cells ex vivo. Further, a VAP-1 inhibitor can be used in the treatment of bone marrow suppression or bone barrow failure in an individual.Type: ApplicationFiled: January 22, 2021Publication date: February 16, 2023Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa JALKANEN, Imtiaz IFTAKHAR-E-KHUDA
-
Patent number: 10526607Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: GrantFiled: March 25, 2014Date of Patent: January 7, 2020Assignee: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 10247730Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favorable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favorable change or starts to show an unfavorable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.Type: GrantFiled: January 22, 2014Date of Patent: April 2, 2019Assignee: FARON PHARMACEUTICALS OYInventors: Mikael Maksimow, Marko Salmi, Markku Jalkanen, Sirpa Jalkanen
-
Publication number: 20150377885Abstract: This invention concerns methods for monitoring the development of and for treatment of ARDS in a patient. The method for monitoring the development of ARDS is based on comparing the level or activity of the biomarkers obtained in a sample drawn at a later point of time to the levels or activities of the same biomarkers in a sample drawn at a previous point of time. A favourable change in the level or activity of a certain biomarker represents a regression of the disease (recovery of the patient), and, conversely, an adverse change in the level or activity of a certain biomarker represents a worsening of the disease. If, for example, the level or activity for one or more of the biomarkers monitored discontinues to show a favourable change or starts to show an unfavourable change, the treatment of the patient is enhanced by administering a therapeutically active agent useful in the treatment of ARDS.Type: ApplicationFiled: January 22, 2014Publication date: December 31, 2015Applicant: TURUN PATENTTITOIMISTO OYInventors: Mikael MAKSIMOW, Marko SALMI, Markku JALKANEN, Sirpa JALKANEN
-
Patent number: 8975081Abstract: The invention concerns a method for monitoring the development of a disease in a patient, and for assessing the efficacy of a therapy influencing on the CD73 level or activity in the patient, in particular a cytokine therapy or a statin therapy. CD73 in a tissue fluid drawn from the patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.Type: GrantFiled: February 25, 2013Date of Patent: March 10, 2015Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen, Mikael Maksimow
-
Publication number: 20140294760Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: ApplicationFiled: March 25, 2014Publication date: October 2, 2014Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8722045Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: GrantFiled: April 6, 2010Date of Patent: May 13, 2014Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20120115815Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: ApplicationFiled: January 19, 2012Publication date: May 10, 2012Applicant: BIOTIE THERAPIES CORP.Inventors: Sirpa JALKANEN, Marko SALMI, Markku JALKANEN
-
Patent number: 8138151Abstract: This invention relates to novel peptides, discovered by using phage display technique, that bind to VAP-1 (Vascular Adhesion Protein-1). The invention concerns also peptides useful as VAP-1 ligands. Such peptides constitute a portion of natural proteins that are present in the individual. The invention relates particularly to a peptide chain in the leukocyte surface protein, where said peptide chain is useful as a ligand for the VAP-1 molecule and thus facilitates the binding of leukocytes to the vascular endothelium. Furthermore, the invention relates to pharmaceutical and diagnostic compositions for targeting VAP-1 in vivo.Type: GrantFiled: December 18, 2007Date of Patent: March 20, 2012Assignee: Faron Ventures OyInventors: Elina Kivi, Kati Elima, Sirpa Jalkanen
-
Patent number: 8119651Abstract: This invention relates to a method for treatment or prevention of metabolic syndrome and diseases or conditions resulting therefrom in an individual, wherein an effective amount of an amine oxidase enzyme inhibitor is administered to said individual. In addition, the invention relates to a method for inhibiting an amine oxidase enzyme or for treatment or prevention of diseases or conditions benefiting from inhibition of an amine oxidase enzyme in an individual, wherein a vitamin B1, its derivative, its precursor or metabolite is administered to said individual. Finally, the invention relates to a food product comprising an amine oxidase enzyme inhibitor in combination with a foodstuff, a food additive comprising an amine oxidase enzyme inhibitor in combination with a liquid, solid or semisolid carrier.Type: GrantFiled: April 1, 2008Date of Patent: February 21, 2012Assignee: Biotie Therapies Corp.Inventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Publication number: 20120027770Abstract: The invention relates to a novel cell derived from the human body, where said cell comprises a Clever-1 receptor; to a method for affecting the immune system of an individual and for treatment of diseases or conditions related to the function of the immune system and to methods for screening of cancer patients that may respond to an anti-Clever-1 therapy or for diagnosing of a pregnancy complication or for estimating the risk of such complication in a pregnant woman.Type: ApplicationFiled: April 6, 2010Publication date: February 2, 2012Applicant: FARON PHARMACEUTICALS OYInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 7910097Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.Type: GrantFiled: March 5, 2008Date of Patent: March 22, 2011Assignee: Faron Pharmaceuticals OyInventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi
-
Publication number: 20110038922Abstract: This invention relates to small interfering RNAs (siRNAs) that down regulates the expression of vascular adhesion protein 1 (VAP-1) for prevention or treatment of a disease or disorder that benefits from the inhibition or down regulation of VAP-1. Pharmaceutical compositions comprising said siRNAs in combination with pharmaceutically acceptable carriers are also included. Furthermore, the invention concerns expression vectors comprising nucleic acids encoding the siRNA duplexes or the antisense strands of said duplexes in a manner which allows expression of said siRNA duplexes or antisense strands within a mammalian cell. Pharmaceutical compositions comprising said expression vectors in combination with pharmaceutically acceptable carriers are also included.Type: ApplicationFiled: June 12, 2006Publication date: February 17, 2011Applicant: FARON PHARMACEUTICALS OY (A FINNISH COMPANY)Inventors: Sirpa Jalkanen, Markku Jalkanen, Marko Salmi
-
Publication number: 20100316569Abstract: This invention relates to novel peptides, discovered by using phage display technique, that bind to VAP-1 (Vascular Adhesion Protein-1). The invention concerns also peptides useful as VAP-1 ligands. Such peptides constitute a portion of natural proteins that are present in the individual. The invention relates particularly to a peptide chain in the leukocyte surface protein, where said peptide chain is useful as a ligand for the VAP-1 molecule and thus facilitates the binding of leukocytes to the vascular endothelium. Furthermore, the invention relates to pharmaceutical and diagnostic compositions for targeting VAP-1 in vivo.Type: ApplicationFiled: December 18, 2007Publication date: December 16, 2010Applicant: FARON VENTURES OYInventors: Elina Kivi, Kati Elima, Sirpa Jalkanen
-
Publication number: 20100310579Abstract: The invention concerns a method for inhibiting angiogenesis or for treating or preventing cancer or cancer metastasis in an individual. The method is based on the administration of an agent capable of counteracting the influence of or for down-regulating the expression of the vascular adhesion protein 1 (VAP-I). The inhibition of the catalytic activity of VAP-I is especially desirable for inhibiting angiogenesis and for treating or preventing of cancer or cancer metastasis.Type: ApplicationFiled: October 15, 2008Publication date: December 9, 2010Applicant: Faron Ventures OyInventors: Marko Salmi, Sirpa Jalkanen
-
Publication number: 20100209942Abstract: The invention concerns a method for monitoring the development of a disease in a patient, or for assessing the efficacy of a cytokine therapy or a statin therapy in a patient, in which methods CD73 in a tissue fluid drawn from said patient is used as a biomarker. The invention concerns also methods for determining of CD73 protein in a sample drawn from an individual's tissue fluid.Type: ApplicationFiled: October 15, 2008Publication date: August 19, 2010Applicant: FARON PHARMACEUTICALS OY a Finnish companyInventors: Sirpa Jalkanen, Marko Salmi, Markku Jalkanen
-
Patent number: 7727521Abstract: This invention relates to a method for prevention or treatment of ischemia reperfusion injury or multi-organ failure in an individual by administering to said individual an effective amount of an interferon beta.Type: GrantFiled: October 5, 2005Date of Patent: June 1, 2010Assignee: Faron Pharmaceuticals OyInventor: Sirpa Jalkanen
-
Publication number: 20090269303Abstract: This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to the individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor being capable of inducing endothelial CD73 expression, or a combination thereof. In addition, the invention concerns a method for prevention or treatment of a disease or disorder requiring or benefiting from the elevation of the adenosine level in an individual. Furthermore, the invention concerns a method of up-regulating endothelial CD73 expression in an individual by administering to the individual an effective amount of a cytokine or another factor being capable of inducing endothelial CD73 expression, and to a method for prevention or treatment of a disease or disorder requiring or benefiting from up-regulating endothelial CD73 expression.Type: ApplicationFiled: April 24, 2009Publication date: October 29, 2009Applicant: FARON PHARMACEUTICALS OYInventor: Sirpa JALKANEN
-
Patent number: 7534423Abstract: This invention concerns a method of inducing an elevated level of adenosine in an individual by administering to said individual an effective amount of either i) recombinant protein CD73 or ii) a cytokine or another factor-being capable of inducing endothelial CD73 expression, or a combination thereof. Furthermore, the invention concerns a method for prevention or treatment of a disease or disorder requiring or benefiting from the elevation of the adenosine level in an individual, such as inflammatory conditions. Furthermore, the invention concerns a method of up-regulating endothelial CD73 expression in an individual by administering to said individual an effective amount of a cytokine or another factor being capable of inducing endothelial CD73 expression, and to a method for prevention or treatment of a disease or disorder requiring or benefiting from up-regulating endothelial CD73 expression.Type: GrantFiled: March 19, 2004Date of Patent: May 19, 2009Assignee: Faron Pharmaceuticals OyInventor: Sirpa Jalkanen
-
Publication number: 20080267958Abstract: A novel protein Common Lymphatic Endothelial and Vascular Endothelial Receptor-1 (CLEVER-1) is described. CLEVER-1 mediates leukocyte and malignant cell binding to vascular and lymphoid endothelial cells. CLEVER-1 is the first protein that has been reported to mediate both influx into and efflux from the lymph nodes. Also provided are methods of treating inflammation and preventing metastasis of malignant cells by providing an inhibitor of CLEVER-1 binding.Type: ApplicationFiled: March 5, 2008Publication date: October 30, 2008Inventors: Sirpa Jalkanen, Heikki Irjala, Marko Salmi